February 19, 2019

Teva Pharmaceuticals Ltd. has reached a settlement agreement with the Federal Trade Commission resolving three separate antitrust lawsuits.  As part of the settlement, Teva agrees not to engage in so-called reverse-payment settlement agreements that can impede consumer access to generic drugs.  In such “pay-for-delay” settlements, the drug company patent-holder pays the generic drug manufacturer allegedly infringing its patent in exchange for the alleged infringer being in position to be awarded a six-month exclusive right to market the generic drug.  The settlement still requires court approval.  FTC

Tagged in: Pharma Fraud,